Table 1.
Patient-derived tumor xenografts (PDX) models in preclinical evaluation of immune checkpoint monoclonal antibody drugs.
| Target | Name of drug | Type of tumor | Model and Strain | Reference |
|---|---|---|---|---|
| PD-1 | Pembrolizumab and Nivolumab | TNBC | Hu-HSC-PDX (NSG mice) | (51) |
| PD-1 | Pembrolizumab and Nivolumab | NSCLC | Hu-HSC-PDX (NSG mice) | (52) |
| PD-1 | Pembrolizumab | NSCLC | Hu-PBMC-PDX (NSG mice) | (53) |
| PD-1 | Pembrolizumab | HCC | Hu-HSC-PDX (NSG mice) | (54) |
| PD-1 | Nivolumab | NSCLC | Hu-HSC-PDX (NSG mice) | (55) |
| PD-1 | Nivolumab | MRCC | Hu-HSC-PDX (NSG mice) | (56) |
| PD-1 | Nivolumab | CCA | Hu-PBMC-PDX (NSG mice) | (57) |
| PD-1 | Pembrolizumab | Liposarcoma | Hu-HSC-PDX (NSG mice) | (58) |
| CTLA-4 | Ipilimumab and Nivolumab | NPC | Hu-HSC-PDX (NSG mice) | (48) |
| PD-L1 | Atezolizumab | NSCLC | Hu-PBL-PDX (NSG mice) | (59) |
| PD-L1 | Durvalumab | NMIBC | Hu-PBMC-PDX (NOG mice) | (59) |
| PD-L1 | Durvalumab | NMIBC | Hu-PBMC-PDX (NOG mice) | (60) |
NSCLC, Non-small cell lung cancer; HCC, Hepatic cell carcinoma; TNBC, Triple-negative breast cancer; MRCC Metastatic renal cell carcinoma; CCA, Clear cell adenocarcinoma; Squamous cell carcinoma; NPC, Nasopharyngeal carcinoma; NMIBC, Non-muscle invasive bladder cancer; BC, Breast cancer; Hu, Human; HSC, Human stem cell; PBL, Peripheral blood lymphocyte.